MY119030A - Purified immunoglobulin - Google Patents

Purified immunoglobulin

Info

Publication number
MY119030A
MY119030A MYPI91001909A MYPI9101909A MY119030A MY 119030 A MY119030 A MY 119030A MY PI91001909 A MYPI91001909 A MY PI91001909A MY PI9101909 A MYPI9101909 A MY PI9101909A MY 119030 A MY119030 A MY 119030A
Authority
MY
Malaysia
Prior art keywords
reducing conditions
exhibits
preparation
major peaks
reduced sample
Prior art date
Application number
MYPI91001909A
Other languages
English (en)
Inventor
Paul Ian Nicholas Ramage
Geoffrey Allen
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY119030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of MY119030A publication Critical patent/MY119030A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI91001909A 1990-10-17 1991-10-16 Purified immunoglobulin MY119030A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin

Publications (1)

Publication Number Publication Date
MY119030A true MY119030A (en) 2005-03-31

Family

ID=10683866

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI91001909A MY119030A (en) 1990-10-17 1991-10-16 Purified immunoglobulin
MYPI92001385A MY136210A (en) 1990-10-17 1991-10-16 Purified immunoglobulin

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI92001385A MY136210A (en) 1990-10-17 1991-10-16 Purified immunoglobulin

Country Status (29)

Country Link
US (1) US5644036A (OSRAM)
EP (1) EP0504363B2 (OSRAM)
JP (1) JP2638680B2 (OSRAM)
KR (2) KR960015399B1 (OSRAM)
AT (2) ATE162552T1 (OSRAM)
AU (3) AU658926B2 (OSRAM)
BE (1) BE1004226A5 (OSRAM)
BR (1) BR1100358A (OSRAM)
CA (1) CA2069481C (OSRAM)
CH (2) CH681305A5 (OSRAM)
DE (1) DE69128774T3 (OSRAM)
DK (1) DK0504363T4 (OSRAM)
ES (2) ES2081742B1 (OSRAM)
FI (2) FI110003B (OSRAM)
FR (2) FR2668164A1 (OSRAM)
GB (2) GB9022547D0 (OSRAM)
GR (3) GR910100425A (OSRAM)
HU (1) HUT64601A (OSRAM)
IE (1) IE913560A1 (OSRAM)
IL (3) IL102726A (OSRAM)
IT (1) IT1250064B (OSRAM)
LU (1) LU88122A1 (OSRAM)
MX (1) MX9203794A (OSRAM)
MY (2) MY119030A (OSRAM)
NZ (2) NZ240247A (OSRAM)
PT (2) PT99248B (OSRAM)
TW (1) TW283710B (OSRAM)
WO (1) WO1992007084A1 (OSRAM)
ZA (2) ZA918259B (OSRAM)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DK0610447T3 (da) * 1991-10-15 1999-08-23 Btg Int Ltd CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
CA2228128C (fr) † 1995-08-01 2011-03-29 Pasteur Merieux Serums & Vaccins Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379C8 (pt) * 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
ES2321539T3 (es) * 2001-06-05 2009-06-08 Genetics Institute, Llc Procedimientos relativos a la purificacion de proteinas altamente anionicas.
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
WO2004024752A1 (ja) 2002-09-11 2004-03-25 Chugai Seiyaku Kabushiki Kaisha タンパク質精製方法
CN102174533A (zh) 2002-10-15 2011-09-07 英特塞尔股份公司 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
WO2005062893A2 (en) * 2003-12-22 2005-07-14 Genzyme Corporation Anti-cd52 antibody treatment for diabetes
RU2457214C2 (ru) * 2005-03-11 2012-07-27 Вайет Способ хроматографии в режиме слабого распределения
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2429582A4 (en) 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
KR101800467B1 (ko) 2009-05-13 2017-11-22 젠자임 코포레이션 루푸스 치료 방법 및 조성물
EP2695889A1 (en) * 2009-12-29 2014-02-12 Dr. Reddy's Laboratories Limited Protein purification by ion exchange
US20130096284A1 (en) 2010-06-21 2013-04-18 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
TWI715524B (zh) 2013-12-27 2021-01-11 日商中外製藥股份有限公司 等電點低之抗體的精製方法
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
EP3330279B1 (en) 2015-07-31 2022-04-06 Chugai Seiyaku Kabushiki Kaisha Method for purifying composition comprising antibodies with anionic polymer
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
ES2994244T3 (en) 2016-07-25 2025-01-21 Cephalon Llc Affinity chromatography wash buffer
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
EP3950099A4 (en) 2019-03-29 2022-05-18 Asahi Kasei Medical Co., Ltd. Method for purifying protein
JP7295943B2 (ja) 2019-04-08 2023-06-21 旭化成メディカル株式会社 タンパク質含有溶液精製用ポリアミド媒体及びその製造方法
AU2020273072A1 (en) 2019-04-10 2021-12-09 Chugai Seiyaku Kabushiki Kaisha Method for purifying Fc region-modified antibody
WO2022260091A1 (ja) 2021-06-10 2022-12-15 三菱ケミカル株式会社 合成吸着剤、抗体の精製方法及び抗体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
ATE95068T1 (de) * 1988-02-12 1993-10-15 British Tech Group Modifizierte antikoerper.

Also Published As

Publication number Publication date
IT1250064B (it) 1995-03-30
NZ240247A (en) 1994-03-25
CA2069481A1 (en) 1992-04-18
ES2112865T3 (es) 1998-04-16
DE69128774D1 (de) 1998-02-26
FI110003B (fi) 2002-11-15
AU7024294A (en) 1995-01-05
TW283710B (OSRAM) 1996-08-21
CH681305A5 (OSRAM) 1993-02-26
BE1004226A5 (fr) 1992-10-13
DK0504363T3 (da) 1998-09-21
GR920100471A (el) 1994-06-30
AU4521897A (en) 1998-02-12
AU716402B2 (en) 2000-02-24
IL99761A0 (en) 1992-08-18
GB9209529D0 (en) 1992-07-01
ES2081742B1 (es) 1996-10-01
MX9203794A (es) 1992-07-01
GB9022547D0 (en) 1990-11-28
WO1992007084A1 (en) 1992-04-30
ZA926191B (en) 1993-04-16
GR3026588T3 (en) 1998-07-31
PT100988A (pt) 1994-02-28
PT99248B (pt) 1999-04-30
IE913560A1 (en) 1992-04-22
DK0504363T4 (da) 2007-05-29
BR1100358A (pt) 2000-03-28
JP2638680B2 (ja) 1997-08-06
EP0504363B2 (en) 2007-02-07
ZA918259B (en) 1993-04-16
PT99248A (pt) 1993-06-30
FI922824A0 (fi) 1992-06-17
DE69128774T2 (de) 1998-06-04
GR910100425A (el) 1992-09-25
IL102726A (en) 2002-08-14
JPH05504579A (ja) 1993-07-15
FI922824L (fi) 1992-06-17
AU658926B2 (en) 1995-05-04
FR2668164A1 (fr) 1992-04-24
ITRM910788A0 (it) 1991-10-16
ATE162552T1 (de) 1998-02-15
KR960015399B1 (ko) 1996-11-13
AU8729491A (en) 1992-05-20
FI922380A0 (fi) 1992-05-25
HU9202000D0 (en) 1992-10-28
ITRM910788A1 (it) 1993-04-16
FI922380L (fi) 1992-05-25
PT100988B (pt) 1999-08-31
LU88122A1 (fr) 1993-03-15
ATA900791A (de) 1996-06-15
FI110002B (fi) 2002-11-15
EP0504363B1 (en) 1998-01-21
MY136210A (en) 2008-08-29
ES2112865T5 (es) 2007-09-16
IL102726A0 (en) 1993-01-31
KR920703108A (ko) 1992-12-17
CA2069481C (en) 2003-07-29
DE69128774T3 (de) 2007-08-16
NZ244114A (en) 1995-06-27
CH681455A5 (OSRAM) 1993-03-31
AU2532192A (en) 1993-02-11
AU649078B2 (en) 1994-05-12
ES2081742A1 (es) 1996-03-01
FR2668164B1 (OSRAM) 1995-04-14
KR100193314B1 (ko) 1999-06-15
EP0504363A1 (en) 1992-09-23
FR2677997A1 (fr) 1992-12-24
HUT64601A (en) 1994-01-28
US5644036A (en) 1997-07-01
GB2253397A (en) 1992-09-09

Similar Documents

Publication Publication Date Title
MY119030A (en) Purified immunoglobulin
GR3026526T3 (en) Use of antibody-containing preparations for immunosuppression.
AU2671795A (en) Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments
AU5733199A (en) Method for chromatographically purifying insulins
AU7044694A (en) Use of saturated, ring-containing compounds as clearing solvents
AU2808592A (en) Improved method for synthesis of desferrioxamine b, analogs and homologs thereof
GR3021988T3 (en) Anti-viral compounds
AU4441393A (en) Granulocyte-binding antibody fragments, their preparation and use
ES2139267T3 (es) Procedimiento para eliminar impurezas olefinicas de 2h-heptafluoropropano (r 227).
AU2629792A (en) Process for the purification of streptolysin 0, intact streptolysin 0 obtained by this process and its use
IT1241194B (it) Molla per cerniera di alette parasole per automobili.
DE3463143D1 (en) 1-0-alkyl-3-amino-propan-1.2-diol-2-0-phospholipids, process for producing the same and pharmaceutical preparations containing the same
IT1247534B (it) Anticorpo nl07 e relativo procedimento di produzione
IT8206908V0 (it) Antenna televisiva premontata, di ingombro riducibile e di rapido adattamento all'impiego.
TW368505B (en) A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
GB9402047D0 (en) Size exclusion chromatography